Home › Companies › MRKR

Marker Therapeutics

Market cap $14.0M 16.7M shares (10-Q, Nov 13, 2026) × $0.840 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. MT-601 PANACEA trial start1Q 2027MT-601 PANACEA trial start, 1Q 2027, routine
  2. Corporate cash runway update2Q 2027Corporate cash runway update, 2Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

MAR-T · Baylor College of Medicine

Multi-antigen recognizing (MAR) T cell platform — non-genetically modified cell therapy that selectively expands tumor-specific T cells recognizing a broad range of tumor antigens across up to six targets; focus areas include hematologic malignancies and solid tumors including pancreatic cancer and lymphoma.

Targets: NY-ESO-1, PRAME, MAGE-A4, Survivin, WT1, SSX2

MAR-T cells

Multi-antigen recognizing (MAR) T cell platform (formerly multiTAA-specific T cells); non-genetically modified cell therapy that selectively expands tumor-specific T cells recognizing up to six tumor antigens; focus on lymphoma and other oncology indications

Targets: Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4

Capital (as filed)

Cash
$9.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$2.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$9.4M cash, runway second quarter of 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Marker Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Marker Therapeutics (MRKR) - Scientific Deep Dive for and MT-601 and Pipeline Products The science is compelling but the balance sheet is too weak for risk-averse investors to confidently buy a large position, making it a watch-list name rather than an actionable buy.
  2. Avoid UPDATE: Marker Therapeutics (MRKR) - The Dilution Gap Becomes a Reality The reverse split filing confirms the dilution trap, making MRKR a vehicle for nimble day-traders rather than investors, with management obligated to sell equity into any clinical strength.
  3. Avoid UPDATE: Marker Therapeutics (MRKR) - 10-K & Definitive Proxy Drop The definitive proxy confirms the dilution machine is fully set up, with any clinical data spike likely to be immediately met with a deluge of newly minted shares sold into the open market.
  4. Avoid CORRECTION: Marker Therapeutics (MRKR) - MRKR's Dilution Trap is Actually Bigger Than I Thought The actual dilution threat is larger than initially modeled — a 100M+ share ATM authorization rather than a reverse split — making MRKR a dilution machine waiting for a clinical PR to serve as exit liquidity.
  5. Avoid UPDATE: Marker Therapeutics (MRKR) - The Dilution Cannon Gets Loaded Shareholders approved 130M authorized shares, giving management industrial-scale dilution capacity against only 16.6M outstanding, making every catalyst feedstock for the cannon rather than a re-rating.
  6. Avoid UPDATE: Marker Therapeutics (MRKR) - Q1 Numbers, Stretched Runway, Stretched Vendors The runway extension to Q1 2027 is a tactical win for management not shareholders, as it gives them freedom to time the equity raise around the APOLLO catalyst rather than being forced by the calendar.
  7. Avoid UPDATE: Marker Therapeutics (MRKR) - The Catalyst That Didn't Show Up The 1H 2026 APOLLO readout never printed, R&D fell 65% suggesting a program in a holding pattern, and the dilution architecture remains fully loaded and untouched.
  8. Avoid UPDATE: Marker Therapeutics (MRKR) - A Grant, a Pop, and a Quiet Nine-Month Slip A $2.6M FDA grant drove a 15% pop but both named catalysts have now slipped — APOLLO missed 1H 2026 and the pancreatic start moved to Q1 2027 — making the rally feedstock for the dilution cannon.
  9. Avoid UPDATE: Marker Therapeutics (MRKR) - The Cannon Was Never Loaded the Way I Said With the stock below $1, the ATM nearly exhausted, management explicitly planning a stock issuance, and no APOLLO data, staying out is more defensible than selling into strength that no longer exists.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (11)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)